Sunday 18 October 2026
Export EYPT’s income statement to Excel — free account
EyePoint, Inc.
EYPT Healthcare Biotechnology
EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024. In the quarter to June 2026, revenue fell 90.5%, EPS fell 28.2% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.00
0.14
−4.46%
Follow EYPT
| Dec '17 | Jun '18 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 5 | 4 | 3 | 6 | 4 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.27 | 39.09 | 46.40 | 7.94 | 2.45 | 9.53 | 3.29 | 19.04 | 9.69 | 42.66 |
Altman Z-Score |
(24.20) | (7.01) | (8.61) | (8.81) | (7.44) | 0.07 | (4.95) | 3.53 | 0.06 | 8.46 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(60.29) | (17.15) | (22.31) | (22.34) | (17.17) | (0.67) | (9.61) | 0.11 | 0.41 | (3.58) |
Beneish M-Score |
— | — | — | — | (3.83) | (1.88) | (4.03) | (4.31) | (1.28) | (2.16) |
P/Operating CF |
(9.81) | (19.03) | (12.07) | (14.08) | 14.33 | (21.12) | (10.82) | (37.91) | (11.70) | (20.57) |
P/B ratio |
4.99 | 9.90 | 3.78 | 19.41 | 4.56 | 1.91 | 1.41 | 3.29 | 1.25 | 4.37 |
Price to Tangible BV |
5.08 | 0.00 | 18.93 | 0.00 | 0.00 | 2.18 | 1.80 | 3.57 | 1.33 | 4.69 |
EV/Sales |
4.64 | 31.84 | 37.37 | 9.19 | 2.27 | 4.81 | 0.76 | 12.60 | 1.92 | 34.01 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.14) | (4.30) | (4.13) | (3.30) | (5.42) | (3.55) | (0.48) | 309.19 | (0.66) | (4.44) |
EV/FCF |
(1.14) | (4.29) | (4.10) | (3.29) | (5.29) | (3.52) | (0.47) | (360.53) | (0.64) | (4.39) |
Quick Ratio |
3.24 | 1.81 | 2.14 | 2.92 | 3.65 | 9.72 | 4.63 | 5.25 | 7.57 | 8.28 |
Current Ratio |
3.35 | 1.84 | 2.22 | 3.62 | 4.24 | 10.05 | 5.00 | 5.45 | 7.81 | 8.88 |
Net Debt/EBITDA |
0.98 | 0.86 | 0.59 | (0.57) | 0.18 | 3.36 | 1.36 | 4.39 | 2.47 | 1.24 |
Debt/Assets |
0.00% | 24.15% | 22.54% | 65.37% | 42.16% | 14.18% | 22.06% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 1.48 | 0.47 | 5.73 | 2.09 | 0.20 | 0.41 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.40 | 0.07 | 0.08 | 0.27 | 0.42 | 0.21 | 0.19 | 0.17 | 0.11 | 0.08 |
Operating CF/Net income |
1.11 | 0.41 | 0.25 | 1.00 | 0.32 | 0.86 | 0.64 | (0.03) | 0.96 | 1.04 |
Capex/Depreciation |
0.00 | (0.08) | 0.00 | (0.07) | (0.11) | (0.05) | (0.10) | 8.89 | 0.92 | 1.24 |
Interest Coverage |
— | (36.49) | (133.84) | (7.75) | (5.14) | (10.05) | (31.24) | (60.20) | (10,418.14) | (7,376.79) |
| (138.61%) | (424.98%) | (362.69%) | (247.12%) | (337.87%) | (57.58%) | (72.84%) | (39.04%) | (43.42%) | (72.19%) | |
| (98.97%) | (117.70%) | (119.38%) | (75.15%) | (55.13%) | (32.90%) | (46.09%) | (26.44%) | (33.83%) | (59.29%) | |
ROIC |
0.00% | 0.00% | 0.00% | (88.45%) | (189.54%) | (339.83%) | 0.00% | 0.00% | 0.00% | (563,504.63%) |
Return on Tangible Assets |
(144.83%) | (287.43%) | (338.40%) | (185.88%) | (92.91%) | (27.23%) | (73.23%) | (24.69%) | (38.22%) | (77.15%) |
Average Days of Receivables |
12.15 | 43.51 | 39.08 | 203.75 | 100.19 | 181.36 | 136.67 | 6.39 | 5.12 | 7.57 |
Research and Development Expense of Revenue |
191.11% | 546.37% | 355.60% | 75.46% | 50.60% | 77.15% | 119.90% | 140.51% | 307.18% | 704.60% |
Selling, General and Administrative Expense of Revenue |
138.21% | 440.97% | 537.88% | 234.28% | 133.63% | 143.69% | 145.70% | 112.55% | 121.30% | 164.80% |
Intangible Assets out of Total Assets |
0.02 | 0.44 | 0.39 | 0.38 | 0.27 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 91.32% | 0.00% | 22.43% | 16.11% | 20.16% | 34.24% | 26.20% | 84.90% | 88.85% |
Graham Net Nets |
0.19 | (0.17) | 0.05 | (0.14) | (0.12) | 0.45 | 0.65 | 0.29 | 0.72 | 0.20 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(38.74%) | (50.24%) | (70.90%) | (36.13%) | (52.74%) | (16.50%) | (74.79%) | (8.13%) | (31.01%) | (17.30%) |
Free Cash Flow Yield |
(64.96%) | (19.01%) | (19.65%) | (35.20%) | (17.52%) | (14.33%) | (49.30%) | (0.18%) | (31.06%) | (18.17%) |
Revenue per Share |
2.13 | 0.64 | 0.69 | 1.95 | 2.68 | 1.28 | 1.11 | 1.18 | 0.77 | 0.43 |
Operating CF per Share |
(5.80) | (4.74) | (2.66) | (5.44) | (1.12) | (1.74) | (1.74) | 0.05 | (2.24) | (3.28) |
Capex per Share |
0.00 | (0.02) | 0.00 | (0.02) | (0.03) | (0.01) | (0.06) | (0.09) | (0.07) | (0.04) |
Free Cash Flow per Share |
(5.80) | (4.76) | (2.66) | (5.46) | (1.15) | (1.75) | (1.80) | (0.04) | (2.31) | (3.32) |
Cash per Share |
4.78 | 8.39 | 5.32 | 2.13 | 3.50 | 7.36 | 3.87 | 8.51 | 6.59 | 4.18 |
Shareholders Equity per Share |
3.77 | 2.53 | 4.42 | 0.80 | 1.44 | 6.41 | 2.58 | 6.85 | 5.98 | 4.18 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.77 | 2.53 | 4.42 | 0.80 | 1.44 | 6.41 | 2.58 | 6.85 | 5.98 | 4.18 |
Free Cash Flow |
(20.49) | (22.01) | (22.59) | (56.91) | (14.80) | (50.25) | (67.15) | (1.61) | (130.28) | (243.23) |
Working Capital |
12.45 | 18.25 | 26.14 | 30.20 | 48.23 | 214.09 | 138.27 | 281.54 | 334.26 | 291.63 |
Capital Expenditures |
(0.15) | (0.11) | (0.13) | (0.21) | (0.36) | (0.16) | (2.15) | (3.48) | (4.05) | (3.12) |
Net Current Asset Value |
12.40 | (20.07) | 7.07 | (22.92) | (10.06) | 158.75 | 88.82 | 255.94 | 301.34 | 270.77 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.04 | 0.00 | 0.01 | 0.01 | 0.00 | 0.05 | 0.08 | 0.09 | 0.10 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.60 | 5.36 | 4.60 | 8.96 | 5.39 | 7.14 | 16.61 | (0.07) | (0.54) | (0.28) |
Cash ROIC |
(67.77%) | (32.48%) | (22.47%) | (72.73%) | (14.49%) | (11.60%) | (23.92%) | (0.27%) | (18.42%) | (39.73%) |
Accounts Receivable Turnover |
30.04 | 9.80 | 11.95 | 3.40 | 3.31 | 2.66 | 2.45 | 5.64 | 61.29 | 49.87 |
Accounts Payable Turnover |
0.80 | 0.00 | 0.00 | 0.79 | 1.29 | 1.34 | 1.25 | 0.75 | 0.41 | 0.19 |
Inventory Turnover |
0.00 | — | 0.00 | 2.22 | 1.56 | 1.83 | 2.56 | 1.36 | 1.20 | 1.00 |
Average Days of Payables |
455.02 | 0.00 | 0.00 | 569.44 | 301.51 | 329.65 | 259.48 | 512.51 | 1,152.52 | 1,853.27 |
Days of Inventory on Hand |
0.00 | — | 0.00 | 290.42 | 334.48 | 161.41 | 126.52 | 307.79 | 226.65 | 320.30 |
Average Receivables |
0.25 | 0.30 | 0.49 | 6.00 | 10.41 | 13.90 | 16.93 | 8.15 | 0.71 | 0.63 |
Average Payables |
1.02 | 1.98 | 2.79 | 3.42 | 4.50 | 6.10 | 6.65 | 6.21 | 9.11 | 11.11 |
Average Inventory |
— | — | 1.21 | 1.21 | 3.74 | 4.48 | 3.25 | 3.40 | 3.11 | 2.06 |
Average Assets |
18.68 | 45.17 | 74.92 | 75.57 | 82.34 | 177.54 | 221.86 | 267.77 | 386.82 | 391.23 |
Average Common Equity |
13.34 | 12.51 | 24.66 | 22.98 | 13.44 | 101.46 | 140.37 | 181.35 | 301.41 | 321.31 |
Columns are period end dates